Incretin Microdosing for Cardiometabolic Health in People With HIV

Prior treatment

• Weight greater than or equal to 400 pounds \[due to dual X-ray absorptiometry (DXA) machine limitations\] or unexplained weight change greater than or equal to 5% in the 12 weeks prior to entry
• Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study period
• Use of human growth hormone, tesamorelin or anabolic steroids \<12 weeks prior to entry, unless on a stable dose for \>24 weeks prior to entry, or plans to start any of these medications while on study
• Prior bariatric surgery or major gastric surgery or plans for weight reduction surgery while on study
• Untreated, poorly controlled or previously undiagnosed thyroid disease
• Poorly controlled or previously undiagnosed thyroid disease, defined as thyroid-stimulating hormone (TSH) \<0.5 or \>10 milli-international units per liter (mIU/L) at screening
• Active drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements
• Use of planned use of any immunomodulatory therapy HIV vaccine, investigational therapy or tumor necrosis factor (TNF-α) therapy during the study period

Other illness

• Diagnosis of or on treatment for diabetes mellitus (stable metformin dosing for pre-diabetes not excluded)
• Active eating disorder
• Personal or first-degree relative history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
• Known allergy/sensitivity to Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)
• Current serious illness requiring systemic treatment and/or hospitalization, in the opinion of site investigator

Other

• Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period
• Active, severe delayed gastric emptying
• Known retinopathy
• Chronic pancreatitis
• Pregnancy, nursing or plans for either during the study period

• Confirmed human immunodeficiency virus type 1 (HIV-1)
• On antiretroviral therapy (ART) for greater than or equal to 24 weeks prior to entry and no change in regimen in the 12 weeks prior to entry or planned change for the study duration
• HIV-1 ribonucleic acid (RNA) \<200 copies/mL at screening
• BMI greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 if also with greater than or equal to 1 weight-related comorbidity
• If taking anti-inflammatory or blood-pressure-/lipid-/glucose-lowering medications, no change in dose for greater than or equal to 12 weeks prior to entry and no plans to dose escalate for the study duration
• All participants must be willing and able to provide written informed consent and undergo all required study procedures